211-225 of 878
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP
Luhua (Michael) Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's RoundtableAdvancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
David Feller-Kopman, MD
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and HematologyAdjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Yungan Tao
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and HematologyPatient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Yungan Tao
- advertisement
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and HematologyKEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Prof. Markus Hecht
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and HematologyCohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Paul L Swiecicki, MD
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and HematologyAmivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Project Oncology®Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Charles Turck, PharmD, BCPS, BCCCP
Rutika J. Mehta, MD, MPH
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
- advertisement
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Project Oncology®Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Alexis Leonard
